These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16513441)

  • 1. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
    Brass EP; Lewis RJ; Lipicky R; Murphy J; Hiatt WR
    Clin Pharmacol Ther; 2006 Mar; 79(3):165-72. PubMed ID: 16513441
    [No Abstract]   [Full Text] [Related]  

  • 2. Tezosentan. Actelion/Genentech.
    Rossetti E; De Servi S
    Curr Opin Investig Drugs; 2003 Mar; 4(3):323-8. PubMed ID: 12735233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacologic properties and indications of modern vasodilator agents. 2: Indications and side effects of vasodilator agents].
    Langnickel R; Bluth R
    Z Arztl Fortbild (Jena); 1985; 79(20):867-73. PubMed ID: 3936287
    [No Abstract]   [Full Text] [Related]  

  • 4. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of drug discovery for treatment of cardiovascular diseases.
    Kennedy C
    Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription drugs uses and effects.
    Nurs Stand; 2004 Jun 16-22; 18(40):2p. PubMed ID: 15224602
    [No Abstract]   [Full Text] [Related]  

  • 7. [New trends in research on active alkaloid constituents occurring in Chinese medicinal herbs for cardio-cerebrovascular diseases].
    Liu ZZ
    Zhong Yao Tong Bao; 1984 Sep; 9(5):3-7. PubMed ID: 6242381
    [No Abstract]   [Full Text] [Related]  

  • 8. Aptamers as candidate therapeutics for cardiovascular indications.
    Keefe AD; Schaub RG
    Curr Opin Pharmacol; 2008 Apr; 8(2):147-52. PubMed ID: 18222730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Problems in scientific drug therapy from a socio-hygienic point of view].
    Kobler A; Lehmann G
    Z Arztl Fortbild (Jena); 1981 Oct; 75(19):906-8. PubMed ID: 7314685
    [No Abstract]   [Full Text] [Related]  

  • 10. Translating molecular target into drug therapy in cardiovascular disease.
    Bril A; Avkiran M
    Curr Opin Pharmacol; 2008 Apr; 8(2):111-3. PubMed ID: 18294914
    [No Abstract]   [Full Text] [Related]  

  • 11. Cilostazol in the management of vascular disease.
    Dalainas I
    Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomics-based cardiovascular drug development: the challenges are just beginning.
    Mucke HA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):203-5. PubMed ID: 16555679
    [No Abstract]   [Full Text] [Related]  

  • 13. Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials.
    Takagi H; Umemoto T
    Int J Cardiol; 2011 Nov; 153(1):74-6. PubMed ID: 21851996
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular pharmacology in the post-blockbuster era.
    Brandes RP
    Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
    [No Abstract]   [Full Text] [Related]  

  • 15. CO-releasing molecules: avoiding toxicity and exploiting the beneficial effects of CO for the treatment of cardiovascular disorders.
    Foresti R; Motterlini R
    Future Med Chem; 2013 Mar; 5(4):367-9. PubMed ID: 23495681
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular medications.
    Williams S; Wynn G; Cozza K; Sandson NB
    Psychosomatics; 2007; 48(6):537-47. PubMed ID: 18071104
    [No Abstract]   [Full Text] [Related]  

  • 17. The polypill concept.
    Wald NJ; Wald DS
    Postgrad Med J; 2010 May; 86(1015):257-60. PubMed ID: 20448221
    [No Abstract]   [Full Text] [Related]  

  • 18. Between a rock and a hard place.
    Demaria AN
    J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
    [No Abstract]   [Full Text] [Related]  

  • 19. [Calcium inhibitors, nitrate derivatives. Principles and indications of use].
    Macquin-Mavier I; Montagne O
    Rev Prat; 1999 Oct; 49(16):1819-23. PubMed ID: 10578615
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)].
    Scholze J; Müller U
    MMW Fortschr Med; 2006 Oct; 148(42):48. PubMed ID: 17621800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.